NervGen Raises $60M in Public Offering to Advance Lead Drug Candidate

Event summary

  • NervGen Pharma Corp. priced a $60M public offering of 24M common shares and warrants at $2.50 per share.
  • The offering is expected to close on May 26, 2026, subject to customary closing conditions.
  • Proceeds will fund clinical studies for NVG-291, a neuroreparative therapeutic for spinal cord injury.
  • NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA.

The big picture

NervGen's $60M raise underscores the high-stakes race to develop neuroreparative therapies for spinal cord injury, a field with significant unmet medical need. The funding comes as biotech firms increasingly turn to public markets to finance late-stage clinical trials, reflecting both the capital intensity of drug development and the strategic importance of securing regulatory designations like Fast Track and Orphan Drug status.

What we're watching

Clinical Progress
How the $60M infusion will accelerate NVG-291 through clinical trials and impact its timeline for market approval.
Market Dynamics
Whether NervGen can sustain momentum in a competitive neurotraumatic therapeutics space.
Execution Risk
The pace at which NervGen can translate funding into tangible clinical and regulatory milestones.